Home » Newsletters » BioWorld Science

BioWorld Science

Oct. 24, 2014

View Archived Issues

Atara Biotherapeutics doses first patient in phase I study of STM-434

[18F]Fludarabine: a highly sensitive and specific radiotracer for lymphoma

Unum Therapeutics launched with Series A funding

Innocrin Pharmaceuticals created as spin-out of Viamet

Forendo Pharma closes financing round to develop a novel therapy for endometriosis

Ablynx reports results from subcutaneous ALX-0061 bioavailability study

Oramed releases topline results from phase IIa study of oral insulin in type 1 diabetes

Regulus Therapeutics' RG-101 demonstrates human proof of concept in HCV infection

U.S. orphan drug status granted to isavuconazonium for invasive candidiasis/candidemia

TapImmune provides update on PolyStart vaccine platform

Profectus BioSciences receives grants to accelerate Ebola vaccine development

Asubio Pharmaceuticals recruits patients in phase II study of SUN-13837

Nicox's shareholders approve acquisition of Aciex Therapeutics

First-in-human results for oral gut-targeted anti-TNF antibody in acute ulcerative colitis

Vertex presents KONDUCT trial results of ivacaftor in patients with CFTR R117H mutations

Researchers at NewLink Genetics disclose new IDO and TDO inhibitors

Bristol-Myers Squibb divulges new NS5B inhibitors for HCV infection

CCX-507 demonstrates safety and efficacy in phase I trials

Sage Therapeutics begins phase IIa trial of SAGE-547 in essential tremor

New O-GlcNAcase inhibitors patented by Merck KGaA

Immunotech Laboratories plans clinical trials of ITV-1 in Ebola virus infection

Novartis synthesizes new agents for bacterial infections

Flatley Discovery designs a new series of CFTR agents for cystic fibrosis

Phase II MenABCWY vaccine results disclosed

Medivation licenses anti-PD-1 antibody pidilizumab from CureTech

FDA extends PDUFA action date for Natpara BLA

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 24, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 24, 2025.
Researchers discover how glioblastoma tumors dodge chemotherapy
BioWorld MedTech
Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
HIV research is close to a cure but far from ending the pandemic
BioWorld
Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...
ADEL wins $1.04B Sanofi deal for tau-targeting Alzheimer’s drug
BioWorld
ADEL Inc. closed a year-end licensing deal worth up to $1.04 billion with Sanofi SA for ADEL-Y01, a specific tau-targeting Alzheimer’s disease drug candidate in a...